Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update

Posted by on Jun 3rd, 2026

Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totaling 2,664 shares, a drop of 45.1% from the April 30th total of 4,855 shares. Based on an average daily trading volume, of 16,063 shares, the short-interest ratio is presently 0.2 days.

Humacyte Trading Down 25.2%

Humacyte stock traded down $0.02 during mid-day trading on Tuesday, reaching $0.05. The company had a trading volume of 46,307 shares, compared to its average volume of 15,299. Humacyte has a 1 year low of $0.04 and a 1 year high of $0.60. The stock’s 50-day simple moving average is $0.08 and its 200-day simple moving average is $0.11.

About Humacyte

(Get Free Report)

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.

Featured Stories

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.